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Is Kava Safe to Be Used by the Public?
Antoine Al-Achi*
Campbell University, College of Pharmacy and Health Sciences, P.O. Box 1090, Buies Creek, North Carolina 27506, USA
The use of botanical products in the United States and European 
countries is extensive. While the original intention of the Dietary 
Supplements and Health Education Act of 1994 (DSHEA) by the US 
Congress was to use these products for the purpose of “supplementing” 
the diet, however many consumers use them for managing their 
disease states. Among the dietary supplements that have been popular 
among individuals who suffer from anxiety or insomnia is kava (Piper 
methysticum Frost F.) (The word “methysticum” is Greek for intoxicant, 
and “Piper” is for pepper. Taken together, kava is an “intoxicating 
pepper”) [1]. The herb is native to South Pacific region (Melanesia, 
Micronesia, Polynesia, and Hawaii) where it has been in use for 
centuries as a traditional beverage. The natives prepare kava drink by 
masticating the rhizomes which are further diluted with either coconut 
milk or water [2]. South Pacific islanders use the drink to connect to 
their gods and ancestors through religious and ceremonial gatherings, 
to alleviate fatigue, and as a relaxant [3]. The word kava when used by 
the natives refers to both the shrub itself and the psychoactive drink 
that is made from its rhizomes [2]. Kava beverage has a bitter and acrid 
taste which is known by the natives as ‘awa’ [2].
In 2002, kava’s import and use in Europe was greatly hindered by 
the health authorities citing toxicity concerns. In the same year, the 
US Food and Drug Administration (FDA) issued a consumer advisory 
(dated March 25, 2002) concerning the use of kava and its association 
with liver toxicity [4]. The FDA stated that
“Kava-containing products have been associated with liver-related 
injuries – including hepatitis, cirrhosis, and liver failure -- in over 25 
reports of  adverse events in other countries. Four patients required 
liver transplants. In the U.S., FDA has received a report of a previously 
healthy young female who required liver transplantation, as well as 
several reports of liver-related injuries” [4].
In the same advisory, the FDA acknowledged the fact that “liver 
damage appears to be rare” and that “persons who have liver disease 
or liver problems, or persons who are taking drug products that 
can affect the liver, should consult a physician before using kava-
containing supplements” [4]. The European decision and US FDA 
warning concerning kava had major economic implications on the 
nations that exported kava to the West. For example, the Pacific 
Island kava producers claimed an annual loss of $US 200 million over 
kava restriction [5]. This ban was later reversed in many EU member 
countries including Germany and France. Poland remains the only 
EU member that outright bans the use of kava within its territories 
[6]. Unfortunately, kava is not the sole known offender in this area as 
more than 900 drugs, herbs, and toxins are documented to cause liver 
damage in human [7].
Kava rhizomes contain many active ingredients known collectively 
as kavalactones or kavapyrones (most important ones are kavain, 
dihydrokavain, methysticin, dihydromethysticin, yangonin, and 
demethoxyyangonin) [3,8]. The rhizomes also contain components 
known as chalcones (mainly three flavokavins A, B, and C) and a 
volatile oil [3,8]. Kavalactones are metabolized by cytochrome P-450 
(CYPs)mixed function monooxygenase systems in the liver (Phase I 
metabolic pathways), in particular CYP2D6, and by conjugation to 
glutathione (GSH) during Phase II metabolic systems [9]. Lactone 
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hydrolases found in the serum also are involved in kavalactones 
metabolism [9]. The presence of normal enzymatic pathways is 
essential for avoiding the hepatotoxicity associated with Kava [9]. In 
clinical studies, kava extract’s effect on the permeability of glycoprotein 
(P-gp) functions and on various CYP activities was not of significance, 
except for CYP2E1 and CYP1A2 where the extract demonstrated an 
inhibitory effect on their functions [10]. Kavalactones were shown 
to modulate both sodium and calcium channels, to reduce neuronal 
re-uptake of adrenaline and dopamine, to cause reversible inhibition 
of monoamine oxidase B in platelets, to enhance substrate binding 
to gamma-aminobutyric acid (GABA-α) receptors, and to activate 
GABAergic neurotransmission [8].
Although the exact reason by which kava extract exerts its damaging 
effect on the liver remains elusive, various theories have been suggested 
to explain it. The presence of aflatoxin in kava as a contaminant has 
been advocated to be the culprit to this hepatotoxicity as this mold 
is known to be hepatotoxic [11,12]. Another hypothesis proposed 
that the organic solvents used in the preparation of the extract were 
perhaps themselves the culprits for the toxicity in kava products 
sold in the West [13]. However, this does not seem to be plausible as 
hepatotoxicity cases have been documented with preparations made 
with aqueous and organic solvents alike [13]. The presence of specific 
hepatotoxic components in the herbal extract was also suggested to be 
the cause of this toxicity. Specifically, flavokawain B was shown to be 
toxic to liver cells grown in cell culture and in experimental animals 
[14]. This toxicity was reversed by the introduction of exogenous GSH 
[14]. Interestingly, kava extracts prepared with organic solvents (e.g., 
acetone or 96% ethanol solution) were found to lack any GSH in their 
content, whereas those prepared with diluted ethanol solutions (25% 
v/v) or water contained a significant quantity of GSH [9]. Moreover, 
individuals with low reserve of GSH in their system tend to deplete this 
reserve rather quickly when challenged with high doses of kavalactones, 
and this in turn can lead to hepatotoxicity [9] 
It appears that the hepatotoxicity of kava may be avoided if the 
product itself supplies GSH along with kavalactones. The possibility 
of the kava product being contaminated with the mold alfatoxin 
remains a worrisome issue at this junction until it is fully ruled out. 
Thus, regulatory agencies have the obligation to assure the public that 
kava products available on their market are free from any alfatoxin 
contamination and contain an adequate amount of GSH in their 
formula. Unless these two requirements are met, safety issues of kava 
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preparations will continue to be a reality and caution must be exercised 
when recommending kava products for therapeutic use.
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